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Abstract: According to the AML-BFM 2004 Interim, a treatment protocol used in Poland since 2005, presence of FLT3 
internal tandem duplication (FLT3/ITD) qualifies a patient with acute myeloid leukemia (AML) to a high-risk group (HRG). 
The present study was aimed to identify the prevalence of FLT3/ITD in children with AML in Poland and to evaluate its 
prognostic significance in the HRG patients. 
Out of 291 children with de novo AML treated in 14 Polish centers between January 2006 and December 2012, samples 
from 174 patients were available for FLT3/ITD analysis. Among study patients 108 children (61.7%) were qualified to 
HRG. Genomic DNA samples from bone marrow were tested for identification of FLT3/ITD mutation by PCR 
amplification of exon 14 and 15 of FLT3 gene. Clinical features and treatment outcome in patients with and without 
FLT3/ITD were analyzed in the study. 
The FLT3/ITD was found in 14 (12.9%) of 108 HRG children. There were no significant differences between children with 
and without FLT3/ITD in age and FAB distribution. The white blood cells count in peripheral blood at diagnosis was 
significantly higher (p <0.01) in the children with FLT3/ITD. Over 5-year overall survival rate for FLT3/ITD positive 
children was worse (42.4%) comparing to FLT3/ITD negative children (58.9%), but the statistical difference was not 
significant. However, over 5-year survivals free from treatment failures were similar. 
The FLT3/ITD rate (12.9%) observed in the study corresponded to the published data. There was no significant impact of 
FLT3/ITD mutation on survival rates, although further studies are needed on this subject. 
Keywords: FLT3/ITD mutation, acute myeloid leukemia, children, treatment result, high risk group. 
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INTRODUCTION 
Acute myeloid leukemias (AML) are a 
heterogeneous group of diseases of hematopoietic 
system that can be classified by morphology, lineage 
specific antigens and genetics [1]. Despite enormous 
progress that was achieved over the last few decades 
in the treatment of pediatric AML, still approximately 
35-45% of patients have failures of treatment such as a 
refractory disease or relapse [2, 3]. New treatment 
strategies are dramatically needed to improve the 
survival rates in AML. One has revealed new targets 
for possible anticancer therapy exploring the 
knowledge on cancer biology. Precise stratification of 
patients to adequate risk groups is also believed to 
improve treatment results [3, 4]. In AML cytogenetic 
and molecular findings at diagnosis are critical 
determinants of outcome and allow for stratification of 
patients to an adequate risk group. In a new BFM 
treatment protocol (Registry AML-BFM 2012) the 
allocation to a risk group is based mainly on those 
genetic fingerprints [3]. 
According to the AML-BFM 2004 Interim, the 
treatment protocol used in Poland since 2005, 
presence of FLT3 internal tandem duplication 
(FLT3/ITD) qualifies a patient with acute myeloid 
leukemia to a high risk group (HRG) [5]. It is 
noteworthy that prognostic significance of some clinical 
and biological factors are being interpreted differently 
by different study groups (i.e. the NOPHO does not 
consider FLT3/ITD as a poor risk factor, while BFM-
AML group does) [2]. 
The FLT3 (Fms-like tyrosine kinase 3, CD135) is a 
member of the class III tyrosine kinase receptor family, 
which also includes c-FMS, c-kit, and PDGFR 
receptors. The FLT3 receptor in normal bone marrow is 
restricted to hematopoietic stem cells and regulates 
proliferation, differentiation and survival of stem cells. It 
is also expressed in many hematologic malignancies 
including most subtypes of AML, B-cell precursor acute 
lymphoblastic leukemia (ALL), T- cell ALL, and chronic 
myeloid leukemia (CML) in blast crisis [6]. There are 
two different types of FLT3 receptor mutations: internal 
tandem duplication (FLT3/ITD) in the juxtamembrane 
region and activation of a loop mutation (FLT3/ALM) in 
the tyrosine kinase domain. The most common 
mutation of FLT3 in AML is FLT3/ITD, which promotes 
cell proliferation and resistance to apoptosis via the 
constitutive activation of many signaling pathways [6-
8]. The FLT3/ITD is one of the most frequent mutations 
in hematologic malignancies, occurring in CML and 
MDS with similar prevalence (5-10%), and AML (15-
35%) [3, 8, 9]. 
In the present study we determined the prevalence 
and prognostic significance of FLT3/ITD in children with 
AML from HRG in Poland, who were treated according 
the same therapy protocol, and correlated its presence 
with clinical characteristics and outcome. 
PATIENTS AND METHODS 
Between January 2006 and December 2012 two 
hundred and ninety one (291) children (0 – 18 years) 
with de novo AML treated according to AML-BFM-2004 
Interim protocol were enrolled at 14 centres of the 
Polish Pediatric Leukemia/Lymphoma Study Group 
(PPLLSG). In all children, diagnosis of AML was based 
upon bone marrow (BM) examination, including cell 
morphology assessment according to French-
American-British (FAB) classification, cytochemistry, 
and immunophenotyping. Cytogenetic analyses, both 
classical and flurorescence in situ hybrydization (FISH) 
were mandatory. Out of 291 children with de novo 
AML, 174 (59.7 %) had bone marrow samples at 
diagnosis available for FLT3/ITD analysis. Among 
study patients, 108 children (61.7%) were qualified to a 
high risk group (HRG). In the study we focused on 
patients from the HRG, therefore children with Down 
syndrome, as well as M3 FAB, who are stratified to a 
standard risk group, were not a priori analysed. 
Patients with myelodysplastic syndrome and secondary 
AML were also excluded. The treatment protocol and 
risk classification were previously reported and 
described elsewhere [5]. In brief, the AML-BFM-2004 
Interim protocol for HRG consists of two induction 
courses, first: AIE (ARA-C, Idarubicin, Etoposide) and 
second: HAM (high doses ARA-C, Mitoxantron). 
Consolidation therapy includes three courses of 
chemotherapy: AI ( ARA-C, Idarubicin) and haM (ARA-
C, Mitoxantron) and HAE (high doses ARA-C, 
Etoposide). Allogeneic hematopoietic stem cell 
transplantation (HSCT) from an HLA-identical sibling 
donor is indicated for all HRG patients in the first 
remission. Children with leukemic blasts after the 
second induction phase (HAM) or still in aplasia after 
second induction are qualified for allo-HSCT from an 
HLA-matched unrelated donor. Intrathecal treatment 
during chemotherapy and cranial irradiation is also 
used as a prophylaxis as well as therapy [5]. Informed 
consent was obtained from the patient or their care-
givers, according to guidelines based on the principles 
of the revised Declaration of Helsinki. The institutional 
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review board of Jagiellonian University Medical Faculty 
approved the study. 
The genomic DNA polymerase chain reaction 
(PCR) assay of exon 14 and 15 of FLT3 gene was 
performed to identify FLT3/ITD. DNA was extracted 
from EDTA stabilized diagnostic bone marrow 
aspirates by using a DNA extraction kit (MasterPure
TM
 
Purification Kit for Blood Version II, Epicentre
®
 
Biotechnology, USA) according to the manufacturer’s 
instruction. PCR amplification was performed with 
primers 11F, 5’-GCAATTTAGGTAT-GAAAGCCAGC – 
3’ and 12R, 5’ – CTTTCAGCATTTTGACGGCAACC – 
3’ [7]. The PCR reaction was carried out in a mixture of 
25 l containing 100 ng DNA, 200 M dNTP, 1x Pol 
Buffer B, 2 U Perpetual Taq Polimerase (Perpetual Taq 
DNA Polimerase, Eurx, Poland) and 800 nM for each 
primer. PCR consisting of denaturation at 95 °C for 30 
seconds, annealing at 61 °C for 30 seconds and 
extension at 72 °C for 45 seconds for 30 cycles was 
performed on T3Thermocycler, Biometra. There was 
an initial 15-minute denaturation at 95°C and a final 
extension at 72 °C for 5 minutes. The reaction products 
were separated on 3% agarose gel (Prona Agarose 
BIO STANDARD, Prona, Spain) and detected by 
ethidium bromide staining. A normal FLT3 amplification 
product length was 329 bp. The presence of additional 
high-molecular weight band represented the FLT3/ITD 
(Figure 1). 
 
Figure 1: Genomic PCR analysis for FLT3/ITD detection. 
Seven genomic DNA samples from different pediatric patients 
were PCR amplified and resolved on 3% agarose gel. A 
normal FLT3 amplification product length is 329 bp (arrow 
points). High-molecular weight bands represent the 
FLT3/ITD. Cn, non-nucleic acid control. 
The Kaplan-Meier method was used to estimate the 
survival distribution. Differences were compared using 
a log-rank test. The results were expressed by means 
of remission rates, event-free survival (EFS), overall 
survival (OS), and relapse-free survival (RFS). The 
comparison between the groups with and without 
FLT3-ITD was performed by nonparametrical tests: the 
Mann–Whitney U-test and the Kolmogorov-Smirnov 
test. We assumed in the study that treatment failures 
include lack of complete remission (CR) during 6 
weeks since beginning of the treatment, relapse or 
progression of AML, early death (during the first 42 
days from beginning of the treatment) or death due to 
AML progression or relapse. For statistical analyses, 
STATISTICA, version 10, StatSoft Inc. (2011) software 
packages were used. The observation was completed 
on December 30, 2012. For all analyses the p values 
less than 0.05 (p<0.05) were considered statistically 
significant. 
RESULTS 
In the HRG patients consisting of 47 girls and 61 
boys, the median age was 11.2 years (0.2-17.7 years). 
The FLT3/ITD was found in 14 (12.9%) of 108 HRG 
children. In not analyzed standard risk group patients 
FLT3/ITD was detected in 4 out of 66 children (6%). All 
four patients had concomitant PML-RARA mutations 
and M3 AML, therefore those patients were treated 
according to AML-BFM-2004 Interim protocol as SRG 
patients irrespective of FLT3/ITD presence. Laboratory 
and clinical characteristics of patients with and without 
FLT3 mutations were compared (Table 1). There were 
no significant differences between children with and 
without FLT3/ITD in age and FAB distribution (p>0.1). 
We found a stepwise age-dependent increase in the 
number of FLT3/ITD positive patients in the group of 
children aged 1 to 10 years. In infant AML we didn’t 
find FLT3/ITD. The FLT3/ITD mutation was found in 
three out of 27 (11.1%) patients aged 1 to 5, in four 
patients out of 12 aged 5 to 10 (33.3%), in seven 
patients out of 61 (11.4%) aged above 10 years (Table 
2). In FLT3/ITD positive patients there was no 
predominance of any particular FAB subtype, although 
FAB subtypes M6 and M7 were not represented. The 
median age of children with FLT3/ITD was 10.6 years, 
similar to that of patients without FLT3/ITD mutations 
(11.2 years) (p>0.1). The white blood cells (WBC) 
count in peripheral blood as well as leukemic blast cells 
at diagnosis were significantly higher in the children 
with FLT3/ITD. Patients with FLT3/ITD had a 
significantly elevated diagnostic WBC count with a 
median diagnostic WBC count of 88.9 x10
9
/L compared 
with 22.2x10
9
/L for the children without FLT3/ITD (p 
<0.01). Similarly, patients with FLT3/ITD had a 
significantly higher peripheral blood blast percentage of 
79% compared with 43% for patients without FLT3/ITD 
(79.14 ± 23.3% vs 43.6 ± 32.93%, p <0.01). 
However, there were no statistically significant 
difference between children with and without FLT3/ITD 
mutations in regard to percentage of bone marrow 
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blasts at diagnosis (77.6% ±28.2 % vs 68.4 ± 23.2%, 
respectively, p=0.1). 
The achievement of a complete remission (CR), as 
well as percentage of blast cells in bone marrow at day 
15 of chemotherapy are the measures of early 
treatment response. In the total of 108 HRG patients, 
88 (81.6%) children achieved a CR (Table 3). The 
complete remission rate was comparable for both 
groups of patients. Eleven (78.5%) out of 14 patients 
with FLT3/ITD achieved a CR compared with 77 (82%) 
out of 94 children without this mutation. The bone 
marrow blast cells percentage at day 15 above 5% is 
considered as poor response to treatment. There were 
no statistically relevant differences in the number of 
children with bone marrow blast cells >5% at day 15 
between patients with and without FLT3/ITD (p>0.1). 
At least one of treatment failures was observed in 
seven (50%) patients out of 14 with FLT3/ITD, and in 
40 (42%) children out of 94 FLT3/ITD negative 
patients, although the statistical difference was not 
significant (p=0.6). Of the 88 patients who achieved a 
CR, 28 children had a relapse: 5 out of 11 CR patients 
(45%) from the FLT3/ITD positive group and 23 out of 
77 CR patients (30%) from the FLT3/ITD negative 
group (Table 3). 
Over 5-year overall survival rate for FLT3/ITD 
positive children was worse (42.4%) compared to 
FLT3/ITD negative children (58.9%), but the difference 
did not reach statistical significance (Figure 2). 
However, over 5-year survivals free from treatment 
failures were similar for patient with and without 
FLT3/ITD mutation (42.4% vs 45.3%, respectively; 
p=0.68) (Figure 3). 
DISCUSSION  
The aim of the study was to identify the prevalence 
of FLT3/ITD in children with AML in Poland and to 
evaluate its prognostic significance in the HRG 
patients. 
Table 1: Characteristics of HRG AML Patients with or without FLT3/ITD 
 Total with FLT3/ITD without FLT3/ITD p Value 
No. of patients 108 14 94  
Age (year) 
median (range) 
 
11.2 (0.2 – 17.7) 
 
10.6 (2.0 – 17.7) 
 
11.2 (0.2 – 17.6) 
 
>0.1 
Gender  
female 
male 
 
47 
61 
 
5 
9 
 
42 
52 
 
Initial WBC ( 10
9
/L) 
median (range) 
 
28.2 (1.1 – 573) 
 
88.9 (6.4 – 573) 
 
22.2 (1.1 – 570.1) 
 
<0.01 
FAB subtype     
M0 17 (15.7%) 4 (3.7%) 13 (12.0%) 
M1 18 (16.7%) 4 (3.7%) 14 (13.0%) 
M2 16 (14.8%) 3 (2.8%) 13 (12.0%) 
M4 28 (25.9%) 2 (1.9%) 26 (24.1%) 
M5 22 (20.4%) 1 (0.9%) 21 (19.4%) 
M6 1 (0.9%) 0 1 (0.9%) 
M7 6 (5.6%) 0 6 (5.6%) 
>0.1 
WBC – white blood cell count. 
 
Table 2: Frequencies of FLT3/ITD Mutation in Different Age Groups 
 <1 y 1-4,9 y 5-9,9 y >10 y p Value 
No. of patients 8 27 12 61  
No. of FLT3/ITD pos. patients 0 3 4 7 >0.1 
Percentage (%) 0 11 33 11  
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Table 3: Treatment Results of HRG AML Patients with or without FLT3/ITD. 
 Total with FLT3/ITD without FLT3/ITD p Value 
Blast cells in BM at day 15 of chemotherapy 
<= 5 % 77/108 (71.3 %) 10/108 (9.3 %) 67/108 (62.0 %) 
> 5 % 25/108 (23.1 %) 3/108 (2.8 %) 22/108 (20.4 %) 
no data 6/108 (5.6 %) 1/108 (0.9 %) 5/108 (4.6 %) 
>0.1  
Treatment results 
CR 88/108 (81.8%) 11/14 (78.5%) 77/94 (81.9%)  
5-year overall survival 55.6% 42.4% 58.9% 0.505 
Probability of treatment 
failures  
5 – year free survival  
45.6% 42.4% 45.3% 0.681 
Treatment failures 
lack of CR 20/108 (18.5%) 3/14 (21.4%) 17/94 (18.0%) 
relapse of AML 28/88 (31.8%) 5/11 (45.4%) 23/77 (29.8%) 
progression of AML 4/108 (3.7%) 1/14 (7.1%) 3/14 (3.2%) 
 
early death 7 (6.5%) 2 (14.3%) 5 (5.3%)  
death due to AML progression 
or relapse 
24/108 (22.2%) 4/14 (28.6%) 20/94 (21.3%)  
BM – bone marrow; CR – complete remission; OS - overall survival. 
 
 
Figure 2: Overall survival (OS) for children with and without FLT3/ITD mutation. 
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Figure 3: Probability of treatment failures free survival for children with and without FLT3/ITD mutation. 
The FLT3/ITD rate (12.9%) observed in the study 
corresponded to the previously published data [3, 6, 8, 
9, 10]. Many studies have shown that presence of 
FLT3/ITD is an independent prognostic factor for poor 
outcome in AML [11, 12-14]. The prognostic 
significance of FLT3/ITD in the presented study was 
less pronounced than in other studies. There were 
comparable remission rates in both groups (78.5% vs 
82%), although relapse rate was higher in FLT3/ITD 
positive children. Of the 88 patients of HRG who 
achieved a CR, 28 children had a relapse: 5 out of 11 
CR patients (45%) from the FLT3/ITD positive group 
and 23 out of 77 CR patients (30%) from the FLT3/ITD 
negative group. Over 5-year overall survival rate for 
FLT3/ITD positive children was worse (42.4%) 
compared to FLT3/ITD negative children (58.9%), but 
the difference did not reach statistical significance. We 
could not demonstrate clearly prognostic impact of 
FLT3/ITD in our study, probably because we didn’t 
analyze the presence of ITD-allelic ratio (mutant to wild 
type allelic ratio), which was shown to be strongly 
connected with a poor outcome. High allelic ratio of ITD 
is associated with poor prognosis [3, 4, 8, 13]. 
Accompanying translocations, such as t(5;11) or 
presence of additional mutation of WT1 or NPM1, can 
also modify the prognostic value of the FLT3/ITD [3, 4, 
8, 15-19]. In study by de Jonge et al. patients with 
mutated NPM1 and FLT3/ITD had unfavourable 
prognosis if they had a WBC count greater than 
100x10
9
/L or ITD allelic ratio was greater than 1. 
Patients with a WBC count below 100x10
9
/L and ITD 
allelic ratio of 1 or less were considered to have 
favourable prognosis [20].  
We have demonstrated the association of FLT3/ITD 
with leucocytosis and increased peripheral leukemic 
blasts cell count, which is consistent with most of the 
previous reports [7-9, 16]. The FLT3 mutations (both 
FLT3/ITD and FLT3/ALM) has been also found to be 
associated with leucocytosis in acute promyelocytic 
leukemia [21].  
The frequency of FLT3/ITD increases with the 
patient’s age, it is rare in infant AML, reaches 5-10% in 
age 5 to 10 years, about 20% in young adults, and 
increases above 35% in patients older than 55 years 
[3, 8, 9]. Our current study showed also a stepwise 
age-dependent increase in the number of FLT3/ITD 
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positive patients, although there were no significant 
differences between children with and without 
FLT3/ITD in age distribution (p>0.1) (Table 2). The 
increase in prevalence of patient with FLT3/ITD 
mutation from 11% in patients aged 1 to 5 to 33% in 
children aged 5 to 10, and subsequent decline to 11% 
in children above 10 years, was probably a result of a 
small number of patients, especially in children aged 5 
to 10 years. Meshinchi et al. suggested that age-
associated increase in the prevalence of FLT3/ITD 
mutation can explain the pathology of FLT3/ITD in 
evolution of AML. Previously acquired, early 
preluekemic hit leads to a minor clone development 
with maturation arrest. Such population maybe 
quiescent until FLT3/ITD is acquired, and the 
probability of this increases with age of the patients [8].  
The prognostic value of FLT3/ITD in pediatric AML 
remains to be explained. Early studies showed a poor 
outcome of patients with present FLT3/ITD [7, 11], 
however later, larger studies suggested a more modest 
impact on outcome [22, 23]. Some studies 
demonstrated that the presence of FLT3/ITD was an 
independent prognostic factor for poor outcome in AML 
[12- 14]. However, differences in the treatment 
outcome were reported depending on FLT3/ITD mutant 
to wild-type ratio (ITD allelic ratio), length of FLT3, as 
well as on an accompanying translocations such as 
t(5;11) or presence of additional mutation of WT1 or 
NPM1 [3, 4, 8, 13, 15, 20, 23, 24]. 
There are much greater hopes for FLT3/ITD 
mutations. Not only is it considered a genetic fingerprint 
guiding the intensity of treatment in children, but also it 
could be used as a marker for monitoring of minimal 
residual disease [18, 25] or a target point for new drugs 
[26, 27]. Furthermore, the FLT3 tyrosine kinase is 
believed to be the most reasonable target protein in 
AML. Currently several potent FLT3 kinase inhibitors 
are being tested in clinical studies (Lestaurtinib - Levis, 
Midostaurin - Stone), however sorafenib has been the 
most extensively investigated first generation FLT3 
inhibitor so far [26-29].  
In conclusion, the present study demonstrates no 
significant impact of FLT3/ITD mutation on survival 
rates in HRG children. The observed differences in 
treatment outcome for children with FLT3/ITD positive 
AML suggest that biologic and clinical differences exist 
between various types of FLT3/ITD mutations. Larger 
prospective studies are needed to evaluate further the 
role of FLT3/ITD and its potential use as targetable 
lesion in future therapies.  
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